logo
  Join        Login             Stock Quote

Biogen Idec (BIIB) Earnings Fall, Miss Estimates For Q4; Revenue Up 7 Pct

 January 28, 2013 06:56 AM
 


(By Balachander) Biogen Idec Inc. (NASDAQ: BIIB) posted a fall in quarterly earnings as higher cost and expenses offset revenue growth and the biotechnology company issued its forecast for 2013.

On a non-GAAP basis, earnings per share (EPS) declined 7.3 percent to $1.40 and missed market expectations of $1.46 for the fourth quarter.

GAAP net income attributable to Biogen Idec also decreased 2.7 percent to $292 million from the year-ago period.

Revenue rose 7 percent to $1.4 billion versus consensus estimates of $1.39 billion. Revenue from the company's multiple sclerosis (MS) drugs Tysabri and Avonex grew 10 percent and 7 percent, respectively.

[Related -Biogen Idec Inc (BIIB): Top Reasons To Own Biogen Idec]

Total cost and expenses increased 7.6 percent.

For 2012, the company earned $6.53 on a non-GAAP basis on revenue of $5.5 billion.

Looking ahead for the full year 2013, the company expects non-GAAP EPS in the range of $7.15 to $7.25 on revenue growth of roughly 10 percent. Analysts expect EPS of $7.27 on revenue of $5.98 billion.

"We are poised to begin what we expect will be a remarkable period of growth, driven by our promising compounds including TECFIDERA and Peginterferon beta-1a for MS, and both Factor VIII and Factor IX for hemophilia," commented CEO George Scangos.

The stock, which has been trading in the 52-week range of $114.53 to $157.18, closed Friday's regular trading at $146.20.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageHow Apple Could Send This Emerging Market Into Overdrive

Don't get distracted by the alphabet soup of emerging market investing -- there are other areas to get read on...

article imageJobless Claims Fell Last Week, Underlining Bullish Trend

New filings for unemployment benefits fell 2,000 to a seasonally adjusted 291,000 for the week through read on...

article image26.25% Annual Return With Lobbying Stocks?

I found an interesting portfolio investing idea: Invest into stocks that spend a huge amount of money to read on...

article imageGlobal Economic Picture Worsens Further.

The Markit PMI Indexes for November are out for a number of countries this morning, and almost all were read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.